Los Angeles · California
Greater Los Angeles has a long history in implantable electronics and drug delivery, and a growing share of new device ideas now come from its academic medical centers. Each path brings its own patent questions.
Much of the Los Angeles area's device history runs through entrepreneur Alfred E. Mann. Among the companies he founded were Pacesetter Systems in 1972, focused on cardiac pacemakers; MiniMed in 1983, focused on glucose monitoring and insulin infusion and later acquired by Medtronic; Advanced Bionics in 1993, which developed cochlear implants and neurostimulation systems; and Second Sight in 1998, which developed implantable visual prostheses. Boston Scientific acquired Advanced Bionics, then located in Valencia, in 2004.
That lineage is still visible. Boston Scientific's neuromodulation division is headquartered in Valencia in the Santa Clarita Valley. MiniMed, which Medtronic announced in 2025 it would separate from its business, completed an initial public offering in March 2026 and is headquartered in Northridge.
In recent years the region's academic and hospital institutions have built more formal channels for device commercialization. Cedars-Sinai Technology Ventures supports inventions from disclosure through patent protection, development, and licensing or company formation, with an emphasis on medical devices and digital health, and the Cedars-Sinai Accelerator works with outside health technology companies. UCLA Biodesign brings together the medical school, UCLA Health, and the Anderson and Samueli schools to train fellows in needs-driven device innovation. The Alfred E. Mann Institute for Biomedical Engineering at USC, founded in 1998, invests in and helps commercialize biomedical technology invented at USC. SoCalBio, the Life Science Association of Southern California, supports biotech, medtech, and pharmaceutical companies across the region.
Those threads suggest several patent priorities. Implantable stimulation and infusion products have been developed and patented for decades, so new entrants should expect dense prior art around leads, stimulation programming, pumps, and sensors, and should budget for thorough clearance work. Implantable products also have long development and product lives, which makes continuation practice and attention to patent term more valuable. Inventions from hospital physicians or university researchers usually carry institutional ownership, so license scope, revenue terms, and the handling of improvements should be settled before a company raises money. Where an institute has invested development funding, its rights in resulting improvements deserve particular attention.
Patent Strategy Considerations
Neuromodulation and infusion technologies have long patent histories. Early searching helps focus claims on real differences and identifies issued claims to design around.
Implantables can take years to reach market and remain in use for years after. Continuation filings and term planning help keep protection aligned with the commercial life of the device.
Physician and faculty inventions typically belong to the institution first. License scope and improvement rights should be clear before investors rely on the portfolio.
How Engagements Work
Knechtel Law Group is based in Carefree, Arizona. Patent prosecution and counseling before the U.S. Patent and Trademark Office is federal practice, and engagements with Los Angeles-area companies are handled directly by senior counsel by video and in person as needed. Matters that turn on state law may call for local counsel.
Request a Confidential ConsultationCommon Questions
No. Representation before the USPTO is federal, and a registered patent attorney may represent applicants anywhere in the United States. Knechtel Law Group is based in Carefree, Arizona. California-law issues, such as employment or corporate matters, or litigation in a California court may call for counsel admitted in California.
It depends on your employment terms and the hospital's intellectual property policy, which often claim inventions made with institutional time or resources. Review those documents, and consider disclosing to the technology transfer office, before discussing the idea with investors or companies.
A U.S. utility patent generally expires 20 years from its earliest non-provisional filing date, and implantables can spend much of that period in development and clinical study. Filing strategy, continuation applications, and any available term adjustments affect how much protection remains once the product is sold.
Discuss Your Portfolio
Schedule a confidential consultation to discuss your technology, your existing portfolio, and your plans.
Request a Confidential Consultation